Cytokinetics Drug Helps ALS Patients in Small Trial

Cytokinetics has completed its clinical trial of a troponin activating drug, CK-2017357, in a small cohort of ALS patients. A subset of patients reported improved muscle strength after treatment, suggesting that this drug holds promise as a quality-of-life enhancing therapy for ALS patients.

Click here to read more.

Share this: